PRKAA1 and mitochondrial disease: Metformin and resveratrol activate AMPK indirectly by inhibiting the mitochondrial ETC and thereby increasing AMP, a mechanism that may be poorly suited for patients with mitochondrial disease stemming from primary ETC abnormalities.